Samidorphan-d4
Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C21H22D4N2O4
- Masse moléculaire:374.47
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform Opioid Receptor
More
Activité biologique
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled Cas 852626-89-2
-
Masse moléculaire 374.47
-
Formule C21H22D4N2O4
-
SMILES
O=C(N)C1=CC=C(C[C@H]([C@@]2(CC3)O)N(CC4)CC5C([2H])([2H])C5([2H])[2H])C([C@]42CC3=O)=C1O
-
Synonyms
ALKS-33-d4; RDC-0313-d4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[2]. McElroy SL, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013 Apr;46(3):239-45. [Content Brief]
[3]. Rehan ST, et al. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg (Lond). 2022 Jun 30;79:104115. [Content Brief]
[4]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)